Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 150
    records per page




    Community factors and excess mortality in first wave of the COVID-19 pandemic MESHD.

    Authors: Bethan Davies; Brandon L Parkes; James Bennett; Daniela Fecht; Marta Blangiardo; Majid Ezzati; Paul Elliott; Cameron Martino; Rachel Diner; Gibraan Rahman; Daniel McDonald; George Armstrong; Sho Kodera; Sonya Donato; Gertrude Ecklu-Mensah; Neil Gottel; Mariana Salas Garcia; Leslie Chiang; Rodolfo A. Salido; Justin P. Shaffer; MacKenzie Bryant; Karenina Sanders; Greg Humphrey; Gail Ackermann; Niina Haiminen; Kristen L. Beck; Ho-Cheol Kim; Anna Paola Carrieri; Laxmi Parida; Yoshiki Vazquez-Baeza; Francesca J. Torriani; Rob Knight; Jack Gilbert; Daniel Sweeney; Sarah M. Allard; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas

    doi:10.1101/2020.11.19.20234849 Date: 2020-11-22 Source: medRxiv

    Risk factors for increased risk of death MESHD from Coronavirus Disease MESHD 19 ( COVID-19 MESHD) have been identified1,2 but less is known on characteristics that make communities resilient or vulnerable to the mortality impacts of the pandemic. We applied a two-stage Bayesian spatial model to quantify inequalities in excess mortality at the community level during the first wave of the pandemic in England. We used geocoded data on all deaths in people aged TRANS 40 years and older during March-May 2020 compared with 2015-2019 in 6,791 local communities. Here we show that communities with an increased risk of excess mortality had a high density of care homes, and/or high proportion of residents on income support, living in overcrowded homes and/or high percent of people with a non-White ethnicity (including Black, Asian and other minority ethnic groups). Conversely, after accounting for other community characteristics, we found no association between population density or air pollution and excess mortality. Overall, the social and environmental variables accounted for around 15% of the variation in mortality at community level. Effective and timely public health and healthcare measures that target the communities at greatest risk are urgently needed if England and other industrialised countries are to avoid further widening of inequalities in mortality patterns during the second wave.

    Gout HP, rheumatoid arthritis HP rheumatoid arthritis MESHD and the risk of death from COVID-19 MESHD: an analysis of the UK Biobank

    Authors: Ruth Topless; Amanda Phipps-Green; Megan Leask; Nicola Dalbeth; Lisa Stamp; Philip Robinson; Tony Merriman; Tjede Funk; Lisa Ferland; Nick Bundle; Jan C. Semenza

    doi:10.1101/2020.11.06.20227405 Date: 2020-11-09 Source: medRxiv

    Objectives To assess whether gout HP and / or rheumatoid arthritis MESHD rheumatoid arthritis HP ( RA MESHD) are risk factors for coronavirus disease MESHD 19 ( COVID-19 MESHD) diagnosis. To assess whether gout HP and / or RA MESHD are risk factors for death from COVID-19 MESHD. Methods We used data from the UK Biobank. Multivariate-adjusted logistic regression was employed in the following analyses. Analysis A: to test for association between gout HP gout MESHD or RA MESHD and COVID-19 MESHD diagnosis in a population-based cohort (n=473,139). Analysis B: to test for association between gout HP gout MESHD or RA MESHD and death from COVID-19 MESHD in a case-control cohort of people who died or survived with COVID-19 MESHD (n=2,073). Analysis C: to test for association with gout MESHD gout HP or RA MESHD and death from COVID-19 MESHD in a population-based cohort (n=473,139) Results Neither RA MESHD nor gout HP gout MESHD associated with COVID-19 MESHD diagnosis in analysis A, nor did RA MESHD or gout HP gout MESHD associate with risk of death MESHD in the COVID-19 MESHD-diagnosed group in analysis B. However RA MESHD associated with risk of death from COVID-19 MESHD using the population-based cohort in analysis C independent of comorbidities and other measured risk factors (OR=1.8 [95% CI 1.2 ; 2.7]). Gout HP was not associated with death from COVID-19 MESHD in the same population-based analysis (OR=1.2 [95% CI 0.9 ; 1.7]). Conclusions RA MESHD and gout MESHD gout HP are not risk factors for COVID-19 MESHD-diagnosis. However RA MESHD, but not gout HP gout MESHD, is a risk factor for death from COVID-19 MESHD in a population-based analysis using the UK Biobank. These findings require replication in larger data sets that also allow inclusion of a wider range of factors.

    Features of alpha-HBDH in COVID-19 MESHD patients with different ages TRANS,outcomes and clinical types: a cohort study

    Authors: Haoming Zhu; Gaojing Qu; Hui Yu; Guoxin Huang; Lei Chen; Meiling Zhang; Shanshan Wan; Bin Pei; Iqra Farooq; Zaigham Habib; Abubakar Hilal; Zain ul Abdin; Ayesha Khaqan; Muhammad Kiwan Akram; Sidra Ashraf; Rutaba Akmal; Sundas Rafique; Khawar Nawaz; Shahroz Arshad; Sohail Ahmad; Kanwal Hayat; Ali Arshad; Muhammad Faisal Nadeem; Muhammad Hassan; Abeer bin Awais; Muhammad Azam; Muhammad Suhail; Sibgha Zulfiqar; Imran Anwar; Saulat Sarfraz; Ayesha Humayun; Amber Malik; Hui Zheng; Talha Mahmud; Mahmood Ayyaz; Ali Ahmad; Muhammad Ashraf; Qazi Abdul Saboor; Mateen Izhar

    doi:10.1101/2020.10.29.20222612 Date: 2020-11-03 Source: medRxiv

    Background: Coronavirus disease-2019 ( COVID-19 MESHD) has spread all over the world and brought extremely huge losses. At present, there is no study to systematically analyse the features of hydroxybutyrate dehydrogenase (alpha-HBDH) in COVID-19 MESHD patients with different ages TRANS, clinical types and outcomes. Methods: Electronic medical records including demographics, clinical manifestation, alpha-HBDH test results and outcomes of 131 hospitalized COVID-19 MESHD patients, with confirmed result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection MESHD, were extracted and analyzed. Results: The alpha-HBDH value in greater than or equal to 61 years old group, severe group and critical group, death group all increased at first and then decreased, while no obvious changes were observed in other groups. And there were significant differences of the alpha-HBDH value among different age groups TRANS, clinical type groups and outcome groups. The optimal scale regression model showed that alpha-HBDH value and age TRANS were related to clinical type. Conclusions: alpha-HBDH value increases in some COVID-19 MESHD patients, obviously in greater than or equal to 61 years old, death MESHD and critical group, indicating that patients in these three groups suffer from more serious tissues and organs damage, higher alpha-HBDH value and risk of death MESHD. The obvious difference between death MESHD and survival group in early stage may provide a approach to judge the prognosis. The accuracy of the model to distinguish severe/critical type and other types is 85.84%, suggesting that alpha-HBDH could judge the clinical type of COVID-19 MESHD patients accurately. In brief, alpha-HBDH is an important indicator to judge the severity and prognosis of COVID-19 MESHD.

    SARS-CoV-2 replication triggers an MDA-5-dependent interferon production which is unable to efficiently control replication

    Authors: Antoine Rebendenne; Ana Luiza Chaves Valadão; Marine Tauziet; Ghizlane Maarifi; Boris Bonaventure; Rémi Planès; Joe McKellar; Sébastien Nisole; Mary Arnaud-Arnould; Olivier Moncorgé; Caroline Goujon; Nicholas A. Crossland; Christopher S. Chen; Darrell N. Kotton; Susan C. Baker; John H. Connor; Florian Douam; Andrew Emili; Mohsan Saeed; Ilayda Sahin; Cavit Kerem Kayhan; Fatma Tokat; Gurler Akpinar; Murat Kasap; Ayse Sesin Kocagoz; Ugur Ozbek; Dilek Telci; Fikrettin Sahin; Koray Yalcin; Siret Ratip; Umit Ince; Guldal Suyen; Ercument Ovali; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; John A Bachman; Benjamin M Gyori; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community

    doi:10.1101/2020.10.28.358945 Date: 2020-10-28 Source: bioRxiv

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic coronavirus to spill over to humans in less than 20 years, after SARS-CoV-1 in 2002-2003 and Middle East respiratory syndrome MESHD ( MERS MESHD)-CoV in 2012. SARS-CoV-2 is the etiologic agent of coronavirus disease MESHD 19 ( COVID-19 MESHD), which ranges from mild respiratory symptoms to severe lung injury MESHD and death MESHD in the most severe cases. The COVID-19 MESHD pandemic is currently a major health issue worldwide. Immune dysregulation HP characterized by altered innate cytokine responses is thought to contribute to the pathology of COVID-19 MESHD patients, which is a testimony of the fundamental role of the innate immune response against SARS-CoV-2. Here, we further characterized the host cell antiviral response against SARS-CoV-2 by using primary human airway epithelia and immortalized model cell lines. We mainly focused on the type I and III interferon (IFN) responses, which lead to the establishment of an antiviral state through the expression of IFN-stimulated genes (ISGs). Our results demonstrate that both primary airway epithelial cells and model cell lines elicit a robust immune response characterized by a strong induction of type I and III IFN through the detection of viral pathogen molecular patterns (PAMPs) by melanoma MESHD melanoma HP differentiation associated gene (MDA)-5. However, despite the high levels of type I and III IFNs produced in response to SARS-CoV-2 infection MESHD, the IFN response was unable to control viral replication, whereas IFN pre-treatment strongly inhibited viral replication and de novo production of infectious virions. Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses.

    Age TRANS-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection MESHD: a result from nationwide database of 5,621 Korean patients

    Authors: Do Hyoung Kim; Hayne Cho Park; AJin Cho; Juhee Kim; Kyu-sang Yun; Jinseog Kim; Young-Ki Lee; Lilian Inoue; Joao Paulo Kitajima; Mayra Kuroki; Cibele Masotti; Tatiana Marques; Alice Reis; Luiz Fernando Reis; Bibiana Santos; Ernande dos Santos; David Schlesinger; Cecilia Sena; Talita Spadaccini; Lucas Taniguti; Surendra Parmar; Dominic Sparkes; Lucy Rivett; Nick K Jones; Sushmita Sridhar; Sally Forest; Tom Dymond; Kayleigh Grainger; Chris Workman; Effrossyni Gkrania-Klotsas; Nicholas M Brown; Michael Weekes; Stephen Baker; Sharon J Peacock; Theodore Gouliouris; Ian G. Goodfellow; Daniela de Angelis; M. Estee Torok

    doi:10.1101/2020.10.26.20220244 Date: 2020-10-27 Source: medRxiv

    Aged TRANS population with comorbidities demonstrated high mortality rate and severe clinical outcome in the patients with coronavirus disease 2019 MESHD ( COVID-19 MESHD). However, whether age TRANS-adjusted Charlson comorbidity index score (CCIS) predict fatal outcomes remains uncertain. This retrospective, nationwide cohort study was performed to evaluate patient mortality and clinical outcome according to CCIS among the hospitalized patients with COVID-19 MESHD infection. We included 5,621 patients who had been discharged from isolation or had died from COVID-19 MESHD by April 30, 2020. The primary outcome was composites of death MESHD, admission to intensive care unit (ICU), use of mechanical ventilator or extracorporeal membrane oxygenation. The secondary outcome was mortality. Multivariate Cox proportional hazard model was used to evaluate CCIS as the independent risk factor for death MESHD. Among 5,621 patients, the high CCIS ([≥]3) group showed higher proportion of elderly TRANS population and lower plasma SERO hemoglobin and lower lymphocyte and platelet counts. The high CCIS group was an independent risk factor for composite outcome (HR 3.63, 95% CI 2.45-5.37, P < 0.001) and patient mortality (HR 22.96, 95% CI 7.20-73.24, P < 0.001). The nomogram demonstrated that the CCIS was the most potent predictive factor for patient mortality. The predictive nomogram using CCIS for the hospitalized patients with COVID-19 MESHD may help clinicians to triage the high-risk population and to concentrate limited resources to manage them.

    Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids

    Authors: Uri Elia; Ramishetti Srinivas; Niels Dammes; Erez Bar-Haim; Gonna Somu Naidu; Efi Makdasi; Ofer Cohen; Dan Peer; Meiling Zhang; Chao Wang; Runkun Wang; Dengpeng Wang; Hongping Wei; Di Liu; Chengqi Yi; Karl-Klaus Conzelmann; Jan Muench; Daniel Sauter; Axel Imhof; Frank Kirchhoff; Konstantin Maria Johannes Sparrer; Katherine Fenstermacher; Zitong Wang; Scott L Zeger; Antony Rosen

    doi:10.1101/2020.10.15.341537 Date: 2020-10-15 Source: bioRxiv

    The novel coronavirus SARS-CoV-2 MESHD has been identified as the causal agent of COVID-19 MESHD and stands at the center of the current global human pandemic, with death MESHD toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple and rapid platform for immunization, and therefore have been employed in recent studies towards the development of a SARS-CoV-2 vaccine. In this study, we present the design of a lipid nanoparticles (LNP)-encapsulated receptor binding domain (RBD) mRNA vaccine. Several ionizable lipids have been evaluated in vivo in a luciferase mRNA reporter assay, and two leading LNPs formulation have been chosen for the subsequent RBD mRNA vaccine experiment. Intramuscular administration of LNP RBD mRNA elicited robust humoral response, high level of neutralizing antibodies SERO and a Th1-biased cellular response in BALB/c mice. These novel lipids open new avenues for mRNA vaccines in general and for a COVID19 MESHD vaccine in particular.

    Dating the emergence of the first case of COVID-19 MESHD in Hubei, China with commercial flights: a retrospective modelling study

    Authors: Liwei Yang; Bochuan Chen

    doi:10.21203/rs.3.rs-92854/v1 Date: 2020-10-14 Source: ResearchSquare

    BackgroundCommercial flights contributed to the early-stage international transmission TRANS of severe acute respiratorysyndrome coronavirus MESHD 2 (SARS-CoV-2). Understand the effect of international and inter-state flights on thevirus transmission TRANS is important to evaluate the initial response of the outbreak. This study investigated thelikely date of the emergence of the first COVID-19 MESHD case in Wuhan, China.MethodsWe constructed a geographical-structured model, including 9122 county-level geographical units in 250different regions or countries, and 26,094,036 flight plans. Using the model, we estimated the date of thenumber of deaths MESHD and the date of first death MESHD caused by COVID-19 MESHD in 155 different countries. We set acertain trigger for country and county level lockdown, and a built-in flight randomizer, to assess thedifferent evidence that can suggest the possibility of different dates to be the emergence of the first COVID-19 MESHD case.FindingsWe found the median number of global deaths MESHD caused by COVID-19 MESHD from 50 trails of our simulation isbetween 853901 and 28432 when the emergence of the first case of COVID-19 MESHD case is within the timeinterval between September 1, 2019 and November 1, 2020. Overall, the average and median R2 of 155countries decrease as the date of the emergence postpone; however, a small increase of R2 is observed whenthe date emergence of the first case of COVID-19 MESHD case is September 22. The deviation of the simulationresult of the deaths from the actual scenario in the eight major epicenters demonstrates a negative trend asthe first case emerges later. A similar pattern can be observed on the date of the first death in these eightcountries, which can be applied to a global scale.InterpretationsWe found that our simulation results can only include the actual number of global deaths caused by COVID-19 MESHD on May 1,2020 inside the 95%PI when the date of the emergence of the first case is betweenSeptember 15, 2019 and October 15, 2020; The lowest deviation can be observed on September 22. Wealso found a decrease of R2 when we deploy later emergence of the first case; unexpectedly, an abnormalincrease of R2 on September 22 is observed. When focusing on the eight major epicenters, we found that thenumber of deaths in these eight countries can only be all included inside the 95%PI when the emergence ison September 15 and September 22. The deviation of the first deaths demonstrates different patternsdepending on the continent, whereas the global average demonstrates a pattern of normal distribution witha maximum of 0.2107 on September 22 after the removal of outliers. This could suggest a high likelihoodof the emergence of the first case of COVID-19 MESHD be around September 15, 2020 and September 22, 2020.

    Coronavirus Disease-2019 Case, Death, and Testing Rates in the United States and Worldwide: Primary Data and Review

    Authors: Ernst J Schaefer; Andrew S Geller; Margaret R Diffenderfer; Latha Dulipsingh; Jeffrey Wisotzkey; Steven B Kleiboeker; Samantha Vanderslott; Cecilia Vindrola-Padros; Rachael Dodd; Samuel Cornell; Tessa Copp; Kirsten J McCaffery; Olav Rooyackers; Lars I. Eriksson; Anders Sonnerborg; Soo Aleman; Kristoffer Stralin; Sara Gredmark-Russ; Jonas Klingstrom; Jenny Mjosberg; - the Karolinska KI/K COVID-19 Study Group; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA

    doi:10.1101/2020.10.13.20172957 Date: 2020-10-14 Source: medRxiv

    ABSTRACT Coronavirus disease-2019 ( COVID-19 MESHD), due to the severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2), has been associated with a world-wide pandemic, with the United States (US) having the largest total number of cases and deaths MESHD (>7 million and >200,000, respectively) at this time. We assessed data as of September 1, 2020 from our combined laboratories and as reported for selected states and countries for case, death, and testing rates per 1 million in the population. Our goal was to elucidate potential causes for the large rate differences observed. SARS-CoV-2 naso-pharyngeal (NP) RNA swab testing in 985,219 US subjects referred to our laboratories by healthcare providers revealed an overall 10.1% positive rate, comparable to the 7.3% rate reported nationwide. In a small subset of 91 subjects, all of whom had been positive for SARS-CoV-2 RNA in NP swabs 2-4 weeks earlier, NP swab testing was twice as likely to be positive (58.6%) as saliva samples (21.5%), based on paired sampling. Our positive rates per state agreed reasonably well with reported Centers for Disease Control and Prevention (CDC) data (r=0.609, P<0.0001) based on 19,898 cases, 593 deaths, and 271,637 tests, all per 1 million in the US population. Louisiana had the highest case rate; New Jersey had the highest death rate; and Rhode Island had the highest testing rate. Of 47 countries, including all countries with populations >50 million, Qatar had the highest case rate; Peru had the highest death rate; and Israel had the highest testing rate for SARS-CoV-2 infection MESHD. Correlations between case rates and death rates as well as testing rates were 0.473 and 0.398 for US states and 0.473 and 0.476 for the various countries, respectively (all P<0.0001). In conclusion, outpatient saliva testing is not as sensitive as NP testing for SARS-CoV-2 RNA detection. While testing is important, without adequate public health measures, it is unlikely that we will get this pandemic under adequate control until vaccines become available.

    Suicide and mental health during the COVID-19 MESHD pandemic in Japan

    Authors: Michiko Ueda; Robert Nordström; Tetsuya Matsubayashi; Rizwan Pervaiz; Muhammad Saleem; Muhammad Faisal Munir; Muhammad Muneeb Ullah Saif; Raul Fuertes; Jordi Candela; Williams Hinojosa; Carlos Duenas; Roberto Gonzalez; Leonor Nogales-Martin; Dolores Calvo; Manuel Carrasco-Moraleja; J. Alberto San Roman; Ignacio J Amat-Santos; David Andaluz Ojeda; Keith R Jerome; Michael R Holbrook; Terry B Gernsheimer; Mark H Wener; Anna Wald; David M Koelle

    doi:10.1101/2020.10.06.20207530 Date: 2020-10-08 Source: medRxiv

    Background: The coronavirus disease MESHD ( COVID-19 MESHD) pandemic is an unprecedented public health crisis, but its effect on suicide deaths is little understood. Method: We analyzed data from monthly suicide statistics between January 2017 and August 2020 and online surveys on mental health among the general population during the COVID-19 MESHD pandemic in Japan. Results: Compared to the last three years (2017-2019), the number of suicide deaths MESHD was lower during the initial phase of the pandemic but subsequently exceeded the past trend. By August 2020, the total number of suicides was 5.69% higher than the average number of suicides in the same month of the previous three years. The largest increase was found in suicides by young women (less than 40 years of age TRANS), with a 40% increase in August 2020 compared to the same month in the past three years. The number of suicides among students and housekeepers in summer months was notably larger in 2020. The survey data indicated that the status of mental health among young women was worse than that of women in other age groups TRANS. In addition, young female TRANS workers were more likely to have experienced a job or income loss in recent months compared to any other groups, suggesting adverse economic conditions surrounding some of these young female TRANS workers. Conclusion: Our results strongly indicate that continuous monitoring of mental health, particularly that of the most vulnerable populations identified in this study, and appropriate suicide prevention efforts are necessary during and in the aftermath of the COVID-19 MESHD pandemic.

    COVID-19 MESHD severity in asthma MESHD asthma HP patients: A multi-center matched cohort study

    Authors: Lacey B. Robinson; Liqin Wang; Xiaoqing Fu; Zachary S. Wallace; Aidan A. Long; Yuqing Zhang; Carlso A. Camargo Jr.; Kimberly G. Blumenthal; Koh Cheng Thoon; Shirin Kalimuddin; Jerry KY Chan; Peter H Seeberger; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205724 Date: 2020-10-05 Source: medRxiv

    Objective: The evidence pertaining to the effects of asthma HP asthma MESHD on Coronavirus disease 2019 MESHD outcomes has been unclear. To improve our understanding of the clinically important association of asthma HP asthma MESHD and Coronavirus disease 2019 MESHD. Methods: A matched cohort study was performed using data from the Mass General Brigham Health Care System (Boston, MA). Adult TRANS ( age TRANS [≥] 18 years) patients with confirmed Coronavirus disease MESHD Coronavirus disease 2019 MESHD and without chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD, cystic fibrosis MESHD, or interstitial lung disease MESHD between March 4, 2020 and July 2, 2020 were analyzed. Up to 5 non- asthma HP comparators were matched to each asthma HP asthma MESHD patient based on age TRANS (within 5 years), sex, and date of positive test (within 7 days). The primary outcomes were hospitalization, mechanical ventilation, and death MESHD, using multivariable Cox-proportional hazards models accounting for competing risk of death MESHD, when appropriate. Patients were followed for these outcomes from diagnosis of Coronavirus disease 2019 MESHD until July 2, 2020. Results: Among 562 asthma HP asthma MESHD patients, 199 (21%) were hospitalized, 15 (3%) received mechanical ventilation, and 7 (1%) died. Among the 2686 matched comparators, 487 (18%) were hospitalized, 107 (4%) received mechanical ventilation, and 69 (3%) died. The adjusted Hazard Ratios among asthma MESHD asthma HP patients were 0.99 (95% Confidence Internal 0.80, 1.22) for hospitalization, 0.69 (95% Confidence Internal 0.36, 1.29) for mechanical ventilation, and 0.30 (95% Confidence Internal 0.11, 0.80) for death MESHD. Conclusions: In this matched cohort study from a large Boston-based healthcare system, asthma MESHD asthma HP was associated with comparable risk of hospitalization and mechanical ventilation but a lower risk of mortality.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.